CINVANTI, in combination with other antiemetic agents, is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic
cancer chemotherapy (HEC), including high-dose cisplatin, and nausea and vomiting associated with initial and repeat courses of moderately emetogenic
cancer chemotherapy (MEC).
Sancuso is the world's first and only transdermal patch of the 5-HT3 receptor antagonist used for the prevention of nausea and vomiting in patients receiving moderately or highly emetogenic
In conjunction, CINVANTI was initially approved based on data demonstrating the bioequivalence of CINVANTI to EMEND IV (fosaprepitant), supporting its efficacy for the prevention of acute and delayed CINV following highly emetogenic
cancer chemotherapy (HEC) and moderately emetogenic
cancer chemotherapy (MEC).
The effect of a standardized ginger extract on chemotherapy-induced nausea-related quality of life in patients undergoing moderately or highly emetogenic
chemotherapy: a double blind, randomized, placebo controlled trial.
A prospective observational survey was conducted on 90 breast cancer patients on AC (Adriamycin/Doxorubicin, Cyclophosphamide) therapy at the dose of 60/600mg/m2 with prophylactic anti-emetic treatment as per ESMO guidelines for moderately emetogenic
therapy at Cancer Hospital Jamshoro Pakistan through a purposive sampling method from 01-01-2016 to 31-12-2016.
Palonosetron Hydrochloride Injection is a 5-HT 3 serotonin receptor indicated in adults for moderately emetogenic
cancer chemotherapy -- prevention of acute and delayed nausea and vomiting associated with initial and repeat courses; highly emetogenic
cancer chemotherapy -- prevention of acute nausea and vomiting associated with initial and repeat courses; and prevention of postoperative nausea and vomiting for up to 24 hours following surgery.
Patients were eligible for this study if they had a malignancy that did not involve bone marrow, were receiving treatment with a moderately to highly emetogenic
regimen, were not pregnant, and had an estimated life expectancy of at least 6 weeks after chemotherapy.
A phase II randomised double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumour patients receiving moderately to highly emetogenic
The Potent Emetogenic
Effects of the Endocannabinoid, 2-AG (2-Arachidonoylglycerol) Are Blocked by A9-Tetrahydrocannabinol and Other Cannnabinoids.
It would also be interesting to investigate whether these techniques can be applied to a pediatric population and patients undergoing surgeries known to be emetogenic
such as head and neck, gynecologic, and urologic procedures.
preoperatively received cancer chemotherapy within past four weeks and emetogenic
radiotherapy within past 8 weeks, etc.